

ASX Announcement and Media Release

13 December, 2004

SciGen Limited and Intercell AG

SciGen Limited and Intercell AG sign an exclusive agreement for the development of a therapeutic Hepatitis B vaccine

International biopharmaceutical company SciGen Limited and Vienna-based biotechnology company Intercell AG announced today the signing of an exclusive agreement for the development of a new therapeutic Hepatitis B virus [“HBV”] vaccine.

A therapeutic HBV vaccine, providing a cure for HBV would significantly reduce the burden of the disease and meet a high medical demand in an attractive market. Currently there is no therapeutic vaccine against Hepatitis B available.

The proposed therapeutic vaccine combines SciGen’s already licensed PreS1-, PreS2-Hepatitis B virus antigen (Sci-B-Vac™) with Intercell’s novel synthetic Immunizer IC 31™ as an adjuvant that induces the type of immune response needed to overcome the infection.

Intercell will formulate the vaccine for the clinical development and both parties will share the development of the product.

Professor Daniel Shouval, internationally recognized liver disease specialist, Dean of the Hadassah University Hospital Medical School in Jerusalem and member of SciGen’s Scientific Advisory Board: “This development provides a very significant opportunity for tackling a widespread and alarming disease. The consequences of chronic hepatitis B infection include liver cirrhosis and liver cancer, both incurable diseases usually with tragic outcomes.”

“Any therapeutic agent developed to comprehensively and successfully treat hepatitis B infection would be regarded by the international medical community as a revolutionary

breakthrough. SciGen's third generation vaccine combined with Intercell's novel adjuvant is a promising development in the quest for such a therapeutic agent", Professor Shouval added.

Gerd Zettlmeissl, Chief Operating Officer of Intercell AG, stated: "This collaboration is another important milestone for both companies. It fully combines the strength of Intercell's latest "state of the art" adjuvant technologies and allows us to further leverage past investments in our technologies and our expertise in therapeutic viral vaccines".

Mark Compton, SciGen's Managing Director: "Whilst this is clearly still at an early stage, the prospect of developing such a blockbuster product is very exciting for both companies. The incidence of hepatitis B in the Asia Pacific Region is reaching alarming levels. Affordable and available treatment for this infection is very much on the agenda for governments and international agencies such as the WHO. The combination of our Sci-B.Vac™ and Intercell's IC31™ allows us to develop an important product for this severe disease."

The Development Agreement between SciGen and Intercell provides a sharing of development costs, a result is a joint ownership of a future product. Further financial details are not disclosed.

Facts on Hepatitis B

Hepatitis B is a serious global public health problem. The virus is transmitted by contact with blood or body fluids of an infected person and leads to inflammation of the liver, liver cirrhosis and cancer.

According to estimations of the WHO (World Health Organisation):

- » 1 out of 3 people have been infected with the hepatitis B virus
- » 400 million people are chronic carriers of HBV
- » Hepatitis B is the leading cause of liver cancer
- » The World Health Organization estimates that hepatitis B infections lead to more than one million deaths every year

Infected and chronic hepatitis B patients are currently treated with interferon or lamivudine, a very expensive therapy which is not affordable to most patients in developing countries. There is no therapeutic vaccine against hepatitis B on the market.

About Intercell

Intercell is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prophylactic and therapeutic treatment of diseases with substantial unmet needs. The Company's unique proposition is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms, as well as in-house GMP facilities. Intercell's technology has been endorsed by collaborative agreements with global pharmaceutical companies including Aventis Pasteur, Merck&Co, Inc. and Statens Serum Institut. Intercell has a broad development pipeline with a vaccine for Japanese Encephalitis about to enter Phase 3, a vaccine for Hepatitis C undergoing Phase 2 trials, and five products focused on infectious diseases in the pre-clinical phase. To date, the Company has raised €100m in external funding from international blue chip investors.

For more information please visit: www.intercell.com

About SciGen

SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.



SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland and the Netherlands.

=====ENDS=====

Media enquiries

Mark Compton

Managing Director & CEO

Telephone: +61 2 9234 1700

Web: www.scigen.com.au